share_log

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8: Initial registration statement for securities to be offered to employees pursuant to employee benefit plans

CRISPR Therapeutics | S-8：員工福利計劃證券登記
美股sec公告 ·  08/06 04:57
牛牛AI助理已提取核心訊息
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
CRISPR Therapeutics AG, a biotechnology company, has filed a Registration Statement on Form S-8 with the Securities and Exchange Commission on August 5, 2024. The filing is for the purpose of registering an additional 1,000,000 common shares at CHF 0.03 per share under the CRISPR Therapeutics AG 2018 Stock Option and Incentive Plan. This move is to facilitate the issuance of stock options and incentive plans to employees and directors. The registration statement incorporates by reference the contents of previous filings related to the 2018 Plan. The company, headquartered in Zug, Switzerland, with executive offices in South Boston, MA, is listed as a large accelerated filer. The filing includes various exhibits, such as the opinion of Swiss counsel regarding the validity of the common shares and the consent of Ernst & Young LLP as the independent registered public accounting firm.
生物技術公司CRISPR Therapeutics AG於2024年8月5日向證券交易委員會提交S-8表格註冊申報。申報目的是註冊另外100萬股普通股，每股價格爲0.03瑞士法郎，根據CRISPR Therapeutics AG 2018股票期權和激勵計劃，以便向員工和董事發放期權和激勵計劃。註冊聲明引用了先前有關2018計劃的各項文件的內容。該公司總部位於瑞士楚格，執行辦公室位於馬薩諸塞州南波士頓，被列爲大型加速提交者。申報包括各種展示，例如瑞士法律顧問對普通股有效性的意見和Ernst& Young LLP作爲獨立註冊會計師事務所的同意。
生物技術公司CRISPR Therapeutics AG於2024年8月5日向證券交易委員會提交S-8表格註冊申報。申報目的是註冊另外100萬股普通股，每股價格爲0.03瑞士法郎，根據CRISPR Therapeutics AG 2018股票期權和激勵計劃，以便向員工和董事發放期權和激勵計劃。註冊聲明引用了先前有關2018計劃的各項文件的內容。該公司總部位於瑞士楚格，執行辦公室位於馬薩諸塞州南波士頓，被列爲大型加速提交者。申報包括各種展示，例如瑞士法律顧問對普通股有效性的意見和Ernst& Young LLP作爲獨立註冊會計師事務所的同意。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

獨立文件3  查看翻譯

獨立文件4  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。